Summit Therapeutics (SMMT) Equity Average (2020 - 2025)
Historic Equity Average for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $225.9 million.
- Summit Therapeutics' Equity Average fell 2864.05% to $225.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.9 million, marking a year-over-year decrease of 2864.05%. This contributed to the annual value of $233.2 million for FY2024, which is 12825.99% up from last year.
- Latest data reveals that Summit Therapeutics reported Equity Average of $225.9 million as of Q3 2025, which was down 2864.05% from $301.9 million recorded in Q2 2025.
- Over the past 5 years, Summit Therapeutics' Equity Average peaked at $413.3 million during Q4 2024, and registered a low of $57.9 million during Q2 2022.
- For the 5-year period, Summit Therapeutics' Equity Average averaged around $156.9 million, with its median value being $110.9 million (2021).
- Per our database at Business Quant, Summit Therapeutics' Equity Average plummeted by 5313.91% in 2024 and then skyrocketed by 50136.67% in 2025.
- Summit Therapeutics' Equity Average (Quarter) stood at $92.8 million in 2021, then skyrocketed by 40.05% to $130.0 million in 2022, then tumbled by 31.87% to $88.5 million in 2023, then surged by 366.86% to $413.3 million in 2024, then crashed by 45.36% to $225.9 million in 2025.
- Its Equity Average was $225.9 million in Q3 2025, compared to $301.9 million in Q2 2025 and $366.5 million in Q1 2025.